NU 0412: A PHASE I/II STUDY OF OXALIPLATIN, 5-FLUOROURACIL AND DOCETAXEL

NU 0412：奥沙利铂、5-氟尿嘧啶和多西紫杉醇的 I/II 期研究

• 批准号: 7376885
• 负责人: Mary Mulcahy
• 金额: $ 1.01万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376885
• 关键词: NU; 0412; PHASE; II; STUDY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The subject is being asked to participate in this research study because he/she has cancer which is not curable by surgery or radiation therapy. In addition, his/her cancer has either grown while on chemotherapy or is likely to grow while on common chemotherapy treatments. This study involves treatment with the chemotherapy drugs: oxaliplatin, 5-fluorouracil, and docetaxel (Taxotere). These drugs have been approved by the Food and Drug Administration (FDA) for the treatment of a wide variety of cancers; however, the combination is considered experimental. The recommended dose and schedule has yet to be determined when using all three chemotherapy drugs together. The purpose of this research study is to evaluate the effects (good and bad) of the combination of oxaliplatin, 5-fluorouracil, and docetaxel. In addition, the study is to determine the highest dose of docetaxel that can be given safely with oxaliplatin and 5-fluorouracil.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。要求受试者参加本研究，因为他/她患有无法通过手术或放疗治愈的癌症。此外，他/她的癌症在化疗期间生长，或者在普通化疗治疗期间可能生长。本研究涉及化疗药物：奥沙利铂、5-氟尿嘧啶和多西他赛（泰索帝）治疗。这些药物已被美国食品和药物管理局（FDA）批准用于治疗各种癌症;然而，该组合被认为是实验性的。当同时使用所有三种化疗药物时，推荐的剂量和时间表尚未确定。 本研究的目的是评价奥沙利铂、5-氟尿嘧啶和多西他赛联合治疗的效果（好与坏）。此外，本研究旨在确定多西他赛与奥沙利铂和5-氟尿嘧啶联合使用时安全的最高剂量。